Preamble 1
THE EUROPEAN COMMISSION,
Having regard to the Treaty on the Functioning of the European Union,
Having regard to Regulation (EC) No 470/2009 of the European Parliament and of the Council of 6 May 2009 laying down Community procedures for the establishment of residue limits of pharmacologically active substances in foodstuffs of animal origin, repealing Council Regulation (EEC) No 2377/90 and amending Directive 2001/82/EC of the European Parliament and of the Council and Regulation (EC) No 726/2004 of the European Parliament and of the Council ( 1 ) , and in particular Article 14, in conjunction with Article 17, thereof,
Whereas:
HAS ADOPTED THIS REGULATION:
recital 1recital 1
(1) Table 1 of the Annex to Commission Regulation (EU) No 37/2010 ( 2 ) sets out the pharmacologically active substances and their classification regarding maximum residue limits (‘MRLs’) in foodstuffs of animal origin.
recital 2recital 2
(2) The substance sodium salicylate is included in that table as an allowed substance.
recital 3recital 3
(3) On 30 September 2022, pursuant to Article 3 of Regulation (EC) No 470/2009, Dopharma B.V. submitted an application to the European Medicines Agency (‘Agency’) for the extension of the existing entry for the substance sodium salicylate to chicken.
recital 4recital 4
(4) On 5 October 2023, the Agency, based on the opinion of the Committee for Veterinary Medicinal Products, set up pursuant to Article 139 of Regulation (EU) 2019/6 of the European Parliament and of the Council ( 3 ) , and having considered the application of Dopharma B.V., recommended the extension of maximum residue limits for the substance sodium salicylate in chicken and the establishment of numerical MRLs.
recital 5recital 5
(5) The Agency also concluded that the extrapolation of the MRLs for sodium salicylate from chicken tissues to the tissues of other poultry species other than turkey is appropriate.
recital 6recital 6
(6) In view of the opinion of the Agency, the Commission considers it appropriate to establish the recommended MRL for sodium salicylate in chicken tissues and to extrapolate it to other poultry species other than turkey, but restricted to animals not producing eggs for human consumption as no residue data were provided for eggs.
recital 7recital 7
(7) Regulation (EU) No 37/2010 should therefore be amended accordingly.
recital 8recital 8
(8) The measures provided for in this Regulation are in accordance with the opinion of the Standing Committee on Veterinary Medicinal Products,
Article 1
The Annex to Regulation (EU) No 37/2010 is amended as set out in the Annex to this Regulation.
Article 2
This Regulation shall enter into force on the twentieth day following that of its publication in the Official Journal of the European Union .
Annex 1ANNEX
In Table 1 of the Annex to Regulation (EU) No 37/2010, the entry for the pharmacologically active substance ‘sodium salicylate’ is replaced by the following:
Pharmacologically active Substance Marker residue Animal Species MRL Target Tissues Other Provisions (according to Article 14(7) of Regulation (EC) No 470/2009) Therapeutic Classification ‘Sodium salicylate NOT APPLICABLE Bovine, Porcine No MRL required NOT APPLICABLE For oral use. Not for use in animals from which milk is produced for human consumption. NO ENTRY All food producing species except fin fish No MRL required For topical use only. Salicylic acid Turkey 400 μg/kg 2 500 μg/kg 200 μg/kg 150 μg/kg Muscle Skin and fat in natural proportions Liver Kidney Not for use in animals producing eggs for human consumption. Anti-inflammatory agents / Non-steroidal anti-inflammatory agents’. Poultry other than turkey 250 μg/kg 250 μg/kg 500 μg/kg 1 000 μg/kg Muscle Skin and fat in natural proportions Liver Kidney